Navigation Links
Lung Cancer Still Lowest in Federal Funding

Research Funding Per Death Drops More in 2007

WASHINGTON, May 16 /PRNewswire-USNewswire/ -- While lung cancer causes one in three cancer deaths, the National Cancer Institute (NCI) invested less than 5% of its $4.8 billion budget in lung cancer research in 2007, according to updated statistics issued by Lung Cancer Alliance (LCA) today.

The two other federal agencies with significant cancer research programs -- Centers for Disease Control and Prevention (CDC) and the Department of Defense (DOD) -- have no money earmarked for lung cancer in 2007.

Expressed in dollars per death, research funding through these three federal sources in 2007 totaled $23,754 for breast cancer, $11,959 for prostate cancer and $5,500 for colon cancer. Lung cancer research spending was $1,414 per death, a 23% drop from $1,829 in research funding per death in 2005.

LCA President & CEO Laurie Fenton Ambrose said these statistics paint a clear picture. "Despite lung cancer's enormous death toll, lung cancer research is still not a priority for our public health policy decision makers."

"The lack of public awareness of the statistics and the stigma of smoking has been a shield for those making these decisions, who also know that lung cancer leaves few survivors to demand more federal research funding money," she said.

"To this we say: No More," said Fenton Ambrose, whose Washington D.C. based national organization is the only one dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.

Lung cancer has the highest number of deaths and the highest death rate of all the cancers, taking more lives each year than breast, prostate, colon, kidney, and melanoma and liver cancers--combined.

"In addition, very few women even know that lung cancer will kill nearly twice as many women as breast cancer, that the number of women with lung cancer has soared or that one in every five women being diagnosed with lung cancer now has never smoked," said Fenton Ambrose.

Over 50% of new lung cancer patients are former smokers, many of whom quit decades ago. Another 10 to 15% have never smoked, with women non-smokers outnumbering men two to one.

"If women knew all these facts, they would be demanding that lung cancer research be funded at least at the same level as breast cancer research if not more," she said.

In 2007 research funding through NCI, CDC and DOD totaled $971,800,000 for breast cancer, $323,500,000 for prostate cancer, $287,000,000 for colon cancer and $226,900,000 for lung cancer.

In 2007 an estimated 52,180 people will die of colon cancer, 40,460 of breast cancer and 27,050 from prostate cancer. A total of 160,390 will die of lung cancer in 2007.

The 5-year survival rate for breast cancer is now 87%, for prostate cancer 99% and for colon cancer 64%. The 5-year survival rate for lung cancer is 15%.

Statistical report attached and can be viewed at

Lung Cancer Alliance ( is the only national non-profit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Media Contact:

Kay Cofrancesco


SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Partnerships Effective Communicators of Cancer Advances
2. Not All Colon Cancer Patients Need Chemotherapy: Study
3. National Coalition for Quality Colorectal Cancer Screening and Care Testifies Before FDA Advisory Panel on Fospropofol Labeling:
4. Bone drug could help prevent the spread of breast cancer
5. Childhood Cancer Survivors Prone to Early Heart Trouble
6. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
7. Cancer patients quality of life directly relates to their survival
8. Blood Test Helps Docs Assess Breast Cancer Treatment
9. Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients
10. Novel enzyme inhibitor paves way for new cancer drug
11. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: